Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MapLight Therapeutics, Inc. ( (MPLT) ) has issued an announcement.
On March 26, 2026, MapLight Therapeutics reported fourth-quarter and full-year 2025 results, highlighting an expanding CNS pipeline and increased R&D investment. The company is advancing ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis, ML-004 for autism spectrum disorder and a next-generation M1/M4 agonist program, ML-055, while ending 2025 with $453.1 million in cash expected to fund operations through 2027.
The Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia is projected to complete enrollment in April 2026, with topline data and results from the fully enrolled Phase 2 IRIS trial of ML-004 in autism expected in the third quarter of 2026. ML-007C-MA also received FDA Fast Track status for Alzheimer’s disease psychosis ahead of the Phase 2 VISTA trial readout planned for 2027, as MapLight’s higher R&D and G&A spending drove its 2025 net loss to $161.2 million but underscored a strategy aimed at near- and midterm clinical catalysts for investors and patients.
The most recent analyst rating on (MPLT) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on MapLight Therapeutics, Inc. stock, see the MPLT Stock Forecast page.
Spark’s Take on MPLT Stock
According to Spark, TipRanks’ AI Analyst, MPLT is a Neutral.
The score is held back primarily by pre-revenue financials with widening losses and increasing cash burn, partially offset by a comparatively strong, low-leverage balance sheet. Recent corporate events (large IPO/private placement and stated runway through 2027) improve near-term funding visibility, while technical indicators are mixed/neutral and valuation cannot be assessed from the provided data.
To see Spark’s full report on MPLT stock, click here.
More about MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing circuit-specific pharmacotherapies for debilitating central nervous system disorders. Founded by leaders in psychiatry and neuroscience, the company uses a discovery platform to identify disease-linked neural circuits and targets conditions including schizophrenia, Alzheimer’s disease psychosis and autism spectrum disorder.
Average Trading Volume: 189,931
Technical Sentiment Signal: Strong Buy
Current Market Cap: $823.1M
See more insights into MPLT stock on TipRanks’ Stock Analysis page.